Registry Study of Medical Therapy in Patients With Angina Pectoris(GREAT)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

1556 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-09-13

Study Completion Date

2023-06-10

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The study will be a multi-center, prospective, cohort study based on registration of Chinese angina pectoris patients. After signing the informed consent, all patients will be screened as per the inclusion and exclusion criteria. Estimated 1500 eligible patients will be enrolled. Two natural cohort will be formed according to whether Nicorandil will be prescribed to patients or not. The baseline information of patients will be recorded and patients will be followed up to observe the effectiveness of different anti-angina regimens. Follow-up visits will be conducted at Month 3, 6, 9, 12 after enrollment. The visits at Months 3, 6 and 9 will be conducted in the form of electronic patient reported outcomes (ePRO) + telephone follow-up, and the visit at Month 12 will be conducted on site. Patients are required to fill in the patient diary records (weekly) during the course of the study.

This study is designed to establish a cohort of Chinese angina pectoris patients and compare the effectiveness of different anti-angina regimens in patients with angina pectoris.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Prospective Registry of the Current Status of Care for Patients With Coronary Artery Disease

NCT05337319

Coronary Artery Disease

RECRUITING

A Multi-Omics Study of Vasospastic Angina

NCT05282511

Vasospastic Angina

UNKNOWN

Chinese Cohort Study of Coronary Heart Disease

NCT00745628

Coronary Heart Diseases

UNKNOWN

A Registry Study on Genetics and Biomarkers of Acute Coronary Syndrome

NCT03752515

Coronary Artery Disease Acute Coronary Syndrome Acute Myocardial Infarction +1 more

UNKNOWN

Correlation of Biomarkers With the Presence and Severity of Coronary Artery Disease

NCT05015270

Coronary Artery Disease

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

After having signed informed consent (Day 0), the patients will be screened for enrollment. About 1500 eligible patients will be enrolled in this study. The basic information of eligible patients including demographic characteristics, history of present illness, past history, Rose questionnaire, vital sign, medication information, SAQ and other optional examination data will be collected at Day 0. At Day 0, the patients will join the study Wechat Mini Program developed for online follow up and patient education by scan the QR code provided by investigators. After enrollment, the following information will be collected by ePRO with WeChat Mini Program or telephone follow up of month 3, 6 and 9: vital sign, medication information, SAQ, AE. The follow up of month 12 will be conducted on site which will collect SAQ, AE and other optional examination data.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Angina Pectoris Real World Study

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Nicorandil group

Patients who are prescribed with Nicorandil with or without other concomitant medication

No interventions assigned to this group

Non-Nicorandil group

Patients who are prescribed with antianginal drugs except Nicorandil

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

\-

1\. Patients with angina pectoris who have evidence of coronary angiography or coronary computed tomography angiography (CTA) performed within 1 year and meet any of the following requirements:

1. Imaging examination shows ≥ 50% stenosis and with typical or atypical angina symptoms;
2. Imaging examination shows \< 50% stenosis; with typical or similar angina symptoms, and the treadmill exercise test or stress echocardiography or radionuclide stress test results are positive;
3. Post-PCI stenosis of left vessels is ≥ 50%; 2. Currently taking or judged by the physicians as suitable to taking at least one oral antianginal drug (e.g., beta-blockers, nitrates, calcium antagonists and potassium channel openers); 3. Have basic reading and writing abilities, and can correctly fill in the Seattle Angina Questionnaire(SAQ) after being trained by the investigator; 4. Able to use smart phones; 5. Voluntarily participate in the study and sign the informed consent form.

Exclusion Criteria

1. Have been diagnosed with malignant tumors that seriously threaten survival and have expected survival time of less than 1 year;
2. Have participated in other clinical studies within the past 1 month;
3. With poor compliance or with other conditions unsuitable for this study as assessed by physicians.

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Yong Zeng

Professor and Director, First Ward of Coronary Heart Disease Center

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Yong Zeng, MD

Role: PRINCIPAL_INVESTIGATOR

Anzhen hospital, Capital medical university

Xiliang Zhao, MD

Role: STUDY_DIRECTOR

Anzhen hospital, Capital medical university

Locations

Explore where the study is taking place and check the recruitment status at each participating site.